1 Beaten-Down Cathie Wood Stock to Buy and Hold
https://www.fool.com/investing/2024/04/04/1-beaten-down-cathie-wood-stock-to-buy-and-hold/?source=iedfolrf0000001
Apr 04, 2024 - This company is innovating where it matters most, which could prove highly lucrative down the road.
0
2 Beaten-Down Cathie Wood Stocks With Massive Potential
https://www.fool.com/investing/2024/03/11/2-beaten-down-cathie-wood-stocks-with-massive/?source=iedfolrf0000001
Mar 10, 2024 - They won't lag the market forever.
0
5 Impressive MedTech Industry Growth Stocks to Buy for 2024
https://www.zacks.com/stock/news/2203633/5-impressive-medtech-industry-growth-stocks-to-buy-for-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2203633
Dec 29, 2023 - Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.
0
Quest Diagnostics (DGX) Advances in Cancer Research With New Deal
https://www.zacks.com/stock/news/2216443/quest-diagnostics-dgx-advances-in-cancer-research-with-new-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2216443
Jan 26, 2024 - Quest Diagnostics' (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.
0
Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi
https://www.zacks.com/stock/news/2227759/iovance-iova-stock-rises-on-fda-nod-for-melanoma-drug-amtagvi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227759
Feb 19, 2024 - The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.
0
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2229711/exact-sciences-exas-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2229711
Feb 21, 2024 - Exact Sciences (EXAS) delivered earnings and revenue surprises of 49.06% and 2.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
https://www.zacks.com/stock/news/2229451/axsome-axsm-stock-falls-despite-q4-earnings-revenue-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2229451
Feb 21, 2024 - Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.
0
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
https://www.zacks.com/stock/news/2261543/boston-scientific-bsx-q1-earnings-beat-estimates-view-raised?cid=CS-ZC-FT-analyst_blog|earnings_article-2261543
Apr 24, 2024 - Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
0
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
https://www.zacks.com/stock/news/2197564/here-s-why-you-should-retain-exact-sciences-exas-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197564
Dec 13, 2023 - Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.
0
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
https://www.zacks.com/stock/news/2226264/exact-sciences-exas-may-report-negative-earnings-know-the-trend-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2226264
Feb 14, 2024 - Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Pages: 12
Page 1